Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Dec 19, 2023

BUY
$35.77 - $51.11 $528,287 - $754,843
14,769 New
14,769 $676,000
Q4 2022

Feb 15, 2023

SELL
$35.77 - $51.11 $136,283 - $194,729
-3,810 Reduced 20.51%
14,769 $677,000
Q2 2022

Aug 15, 2022

SELL
$33.93 - $48.92 $646,400 - $931,974
-19,051 Reduced 50.63%
18,579 $730,000
Q1 2022

May 16, 2022

SELL
$29.74 - $46.0 $862,430 - $1.33 Million
-28,999 Reduced 43.52%
37,630 $1.39 Million
Q4 2020

Feb 12, 2021

SELL
$15.26 - $28.61 $216,692 - $406,262
-14,200 Reduced 17.57%
66,629 $1.39 Million
Q2 2020

Aug 17, 2020

SELL
$11.15 - $24.64 $154,037 - $340,401
-13,815 Reduced 14.6%
80,829 $1.91 Million
Q1 2020

May 13, 2020

BUY
$8.75 - $16.3 $94,080 - $175,257
10,752 Added 12.82%
94,644 $1.12 Million
Q4 2019

Feb 14, 2020

BUY
$7.95 - $11.84 $62,781 - $93,500
7,897 Added 10.39%
83,892 $890,000
Q3 2019

Nov 15, 2019

SELL
$10.82 - $14.25 $252,430 - $332,452
-23,330 Reduced 23.49%
75,995 $865,000
Q2 2019

Aug 12, 2019

SELL
$7.95 - $11.25 $75,922 - $107,437
-9,550 Reduced 8.77%
99,325 $1.12 Million
Q1 2019

May 15, 2019

BUY
$5.95 - $10.19 $151,653 - $259,722
25,488 Added 30.57%
108,875 $881,000
Q4 2018

Feb 15, 2019

BUY
$5.91 - $9.29 $125,693 - $197,579
21,268 Added 34.24%
83,387 $527,000
Q3 2018

Nov 14, 2018

SELL
$6.4 - $9.85 $73,024 - $112,388
-11,410 Reduced 15.52%
62,119 $612,000
Q1 2018

May 15, 2018

SELL
$7.2 - $10.05 $50,047 - $69,857
-6,951 Reduced 8.64%
73,529 $529,000
Q4 2017

Feb 08, 2018

BUY
$7.25 - $15.65 $393,914 - $850,311
54,333 Added 207.8%
80,480 $656,000
Q3 2017

Nov 20, 2017

SELL
$12.0 - $15.0 $299,028 - $373,785
-24,919 Reduced 48.8%
26,147 $379,000
Q2 2017

Aug 16, 2017

BUY
N/A
51,066
51,066 $618,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $3.92B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Public Employees Retirement System Of Ohio Portfolio

Follow Public Employees Retirement System Of Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement System Of Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement System Of Ohio with notifications on news.